
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for…












